MyJournals Home  

RSS FeedsPharmaceuticals, Vol. 14, Pages 926: New Strategies for the Treatment of Atrial Fibrillation (Pharmaceuticals)


15 september 2021 11:00:58

Pharmaceuticals, Vol. 14, Pages 926: New Strategies for the Treatment of Atrial Fibrillation (Pharmaceuticals)

Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia in the clinical practice. It significantly contributes to the morbidity and mortality of the elderly population. Over the past 25–30 years intense effort in basic research has advanced the understanding of the relationship between the pathophysiology of AF and atrial remodelling. Nowadays it is clear that the various forms of atrial remodelling (electrical, contractile and structural) play crucial role in initiating and maintaining the persistent and permanent types of AF. Unlike in ventricular fibrillation, in AF rapid ectopic firing originating from pulmonary veins and re-entry mechanism may induce and maintain (due to atrial remodelling) this complex cardiac arrhythmia. The present review presents and discusses in detail the latest knowledge on the role of remodelling in AF. Special attention is paid to novel concepts and pharmacological targets presumably relevant to the drug treatment of atrial fibrillation.

63 viewsCategory: Medicine, Pharmacology
Pharmaceuticals, Vol. 14, Pages 925: Incident Type 2 Diabetes Risk of Selective Estrogen Receptor Modulators in Female Patients with Breast Cancer (Pharmaceuticals)
Pharmaceuticals, Vol. 14, Pages 927: Population Pharmacokinetic Analysis of Pazopanib in Patients and Determination of Target AUC (Pharmaceuticals)
blog comments powered by Disqus
The latest issues of all your favorite science journals on one page


Register | Retrieve



Copyright © 2008 - 2021 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures News Tweets Nachrichten